Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HDM1002 tablets in adults with type 2 diabetes mellitus inadequately controlled by diet and exercise or metformin
CTR20242121Phase 2Completed
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of conveglipron in type 2 diabetes mellitus (T2DM), sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Jun 2024; status: completed.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20242121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242121.